Selling, General, and Administrative Costs: Incyte Corporation vs Verona Pharma plc

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Incyte Corporation and Verona Pharma plc from 2014 to 2023. Incyte Corporation, a leader in biopharmaceutical innovation, has seen its SG&A expenses grow by over 600% during this period, reflecting its expanding operations and market reach. In contrast, Verona Pharma plc, a smaller player, has experienced a more modest increase of approximately 2,700%, indicating its strategic investments in growth and development. Notably, Incyte's expenses surged significantly in 2022 and 2023, suggesting a strategic pivot or expansion. This data provides a fascinating glimpse into how these companies allocate resources to maintain competitiveness and drive innovation in the ever-evolving biotech landscape.